Table 1.
Characteristics and Univariable Logistic Regression Outcomes of Myelotoxicity
| Categorical Characteristics | Cases (N = 134) | Controls (N = 457) | OR | 95% CI | P-value | ||
|---|---|---|---|---|---|---|---|
| No. | % | No. | % | ||||
| Treatment arm | .015 | ||||||
| TMZ+placebo | 54 | 40.3 | 239 | 52.3 | 1 | ||
| TMZ+BEV | 80 | 59.7 | 218 | 47.7 | 1.6 | 1.01–2.40 | |
| Gender | <.0001 | ||||||
| Male | 52 | 38.8 | 308 | 67.4 | 1 | ||
| Female | 82 | 61.2 | 149 | 32.6 | 3.26 | 2.19–4.86 | |
| KPS | .0356 | ||||||
| 70 | 23 | 17.2 | 52 | 11.4 | 2.45 | 1.20–4.99 | |
| 80 | 42 | 31.3 | 111 | 24.3 | 2.09 | 1.12–3.92 | |
| 90 | 52 | 38.8 | 200 | 43.7 | 1.44 | 0.79–2.62 | |
| 100 | 17 | 12.7 | 94 | 20.6 | 1 | ||
| Surgery | .365 | ||||||
| Subtotal | 55 | 41 | 157 | 34.4 | 1.33 | 0.49–3.68 | |
| Gross total | 76 | 56.7 | 288 | 63 | 1 | ||
| Other | 3 | 2.3 | 12 | 2.6 | 0.95 | 0.26–3.44 | |
| Tumor MGMT Methylation Status | .423 | ||||||
| Unmethylated | 90 | 68.7 | 321 | 72.3 | 1 | ||
| Methylated | 41 | 31.3 | 123 | 27.7 | 1.19 | 0.75–1.85 | |
| BMI | .4839 | ||||||
| Underweight & Normal | 39 | 29.1 | 116 | 25.4 | 1.36 | 0.81–2.29 | |
| Overweight | 60 | 44.8 | 197 | 43.1 | 1.24 | 0.77–1.98 | |
| Obese | 35 | 26.1 | 142 | 31.1 | 1 | ||
| Missing | 0 | 0 | 2 | 0.4 | |||
| Anticoagulant agents | .3368 | ||||||
| No | 128 | 95.5 | 426 | 93.2 | 1.55 | 0.63–3.80 | |
| Yes | 6 | 4.5 | 31 | 6.8 | 1 | ||
| Proarrhythmic potential agents | .2178 | ||||||
| No | 130 | 97 | 431 | 94.3 | 1.96 | 0.67–5.72 | |
| Yes | 4 | 3 | 26 | 5.7 | 1 | ||
| Herbal | .6509 | ||||||
| No | 128 | 95.5 | 432 | 94.5 | 1.24 | 0.50–3.08 | |
| Yes | 6 | 4.5 | 25 | 5.5 | 1 | ||
| Corticosteroids | .3701 | ||||||
| No | 32 | 23.9 | 127 | 27.8 | 1 | ||
| Yes | 102 | 76.1 | 330 | 72.2 | 1.23 | 0.79–1.92 | |
| Anticonvulsants | .0901 | ||||||
| No | 29 | 21.6 | 133 | 29.1 | 1 | ||
| Yes | 105 | 78.4 | 324 | 70.9 | 1.49 | 0.94–2.35 | |
| EIAEDs | .1646 | ||||||
| No | 117 | 87.3 | 374 | 81.8 | 1.49 | 0.85–2.62 | |
| Yes | 17 | 12.7 | 81 | 17.7 | 1 | ||
| Missing | 0 | 0 | 2 | 0.5 | |||
| NEIAEDs | .0472 | ||||||
| No | 77 | 57.5 | 304 | 66.5 | 1 | ||
| Yes | 57 | 42.5 | 151 | 33 | 1.49 | 1.01–2.21 | |
| Missing | 0 | 0 | 2 | 0.5 | |||
| Urine protein/creatinine ratio | .9768 | ||||||
| ≤0.5 | 115 | 85.8 | 393 | 86 | 1 | ||
| >0.5 | 18 | 13.4 | 61 | 13.3 | 1.01 | 0.57–1.78 | |
| Missing | 1 | 0.8 | 3 | 0.7 | |||
| Continuous Characteristics | Median | IQR | Median | IQR | |||
| Age, years | 59 | 51–64 | 58 | 51–65 | 1.00 | 0.98–1.02 | .9693 |
| Creatinine, mg/dL | 0.78 | 0.65–0.90 | 0.83 | 0.70–0.95 | 0.14 | 0.05–0.42 | .0005 |
| Platelet, 103/mm3 | 240.5 | 192–302 | 235 | 193.0–283.5 | 1.00 | 0.99–1.01 | .5535 |
| ANC, 102/mm3 | 60.4 | 35.6–90.0 | 63 | 41.0–90.4 | 1.00 | 0.99–1.01 | .6629 |
| Hemoglobin, g/dL | 13.4 | 12.3–14.2 | 13.5 | 12.5–14.4 | 0.94 | 0.82–1.09 | .4145 |
| WBC, 102/mm3 | 86 | 60–119 | 85 | 64–112 | 1.00 | 0.99–1.01 | .7684 |
| BUN, mg/dL | 17 | 13–22 | 17 | 14–21 | 0.99 | 0.96–1.03 | .7739 |
| Total Bilirubin, mg/dL | 0.4 | 0.3–0.6 | 0.5 | 0.3–0.6 | 0.84 | 0.42–1.71 | .6364 |
| SGOT, u/dL | 20 | 16–26 | 21 | 16–26 | 0.99 | 0.98–1.01 | .6985 |
| SGPT, u/dL | 31.5 | 23–47 | 36 | 25–50 | 0.99 | 0.98–1.01 | .2498 |
| PT, seconds | 11.3 | 10.2–12.7 | 11.1 | 10.2–12.8 | 0.97 | 0.91–1.04 | .3752 |
| PT/INR | 1 | 0.9–1.0 | 1 | 0.9–1.0 | 0.50 | 0.13–1.88 | .3017 |
| TMZ dose, 102 mg | 30.5 | 27.3–33.6 | 31.5 | 28.5–34.7 | 0.97 | 0.95–0.99 | .0439 |
| BSA | 1.87 | 1.72–2.08 | 2 | 1.84–2.18 | 0.15 | 0.06–0.34 | <.0001 |
Abbreviations: ANC, absolute neutrophil count; BEV, bevacizumab; BSA, body surface area; BUN, blood urea nitrogen; CI, confidence interval; EIAEDs, enzyme-inducing anti-epileptic drugs; INR, international normalized ratio; IQR, inter-quartile range; KPS, Karnofsky Performance Status; NEIAEDs, non-enzyme-inducing anti-epileptic drugs; OR, odds ratio; PT, prothrombin time; SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamic pyruvic transaminase; TMZ, temozolomide; WBC, white blood cell count.
Bold values represent factors with a univariable p value <0.15 and were considered for the multivariable model.